ARCHIVES

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

This article is from The Cancer Letter archive.

Vol. 28 No. 32 | September 6, 2002

Download PDF Visit The Full Archive

Related Articles

FDA Softening Its Stance On CME Guidelines; New Version To Be More In Line with ACCME

April 3, 1992

DCT Board Okays Concepts For New Trials In Imaging, Intraoperative RT

June 14, 1985

NCI Increases R01 Grant Payline From 12th to 15th Percentile.

June 29, 2007

CCOPs Favor Ability To Enter Patients On Any Group Study

June 12, 1998

“I’m Not Bummed Out By This” – Broder

December 22, 1994

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

October 2, 2009